Personalized Radiation Therapy for GBM

Abramson Cancer Center at Penn Medicine

Status: Active, not recruiting

Conditions: Glioblastoma

Treatments: Radiation: Radation Therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT03477513

UPCC 24317

Details and patient eligibility

About

The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen
• Age 18 or older
• Ability to give signed informed consent
• Karnofsky Performance Status (KPS) at least 70

Exclusion criteria

• Placement of Gliadel wafers
• Participation in another investigational trial
• Active treatment of another malignancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Single Arm

Experimental group

Description:

Dose-escalated radiation therapy

Treatment:

Radiation: Radation Therapy